Oncolytics Biotech is trading at $0.72, up 5.81% now in pre-market, aligned with broader biotechnology strength; no new company-specific catalyst was identified for September 24, 2026.
- The XBI sector indicator is up 2.61% pre-market, despite weaker major U.S. index futures.
- The latest identifiable company news was positive preclinical pelareorep data announced September 10 involving combination treatment with a pan-RAS inhibitor; it is not fresh enough to establish direct causation today.